Jiahui International Cancer Center is affiliated to Shanghai Jiahui International Hospital and is a strategic cooperative medical center in China with Massachusetts General Hospital and its cancer center. It is led by a number of clinical leaders who represent the forefront of international cancer diagnosis and treatment, providing patients over the age of 14 years with rapid, international-standard cancer diagnosis and treatment services. Jiahui International Cancer Center supports direct payment from more than 50 global mainstream insurance companies and is connected to the Chinese Basic Medical Insurance in order to provide convenient payment options. Services: Anti-tumor drug treatment (chemotherapy, targeted, immune), tumor radiation therapy, tumor surgical treatment, tumor complication management, cancer pain management, palliative care, tumor nutrition, rehabilitation physical therapy, psychological counseling, PICC/PORT insertion and maintenance, HAIC/TACE interventional treatment, etc. Tumor types: Digestive tract tumors (liver cancer, bile duct cancer, stomach cancer, colorectal cancer, pancreatic cancer, esophageal cancer, etc.), breast cancer, lung cancer, urinary system tumors (bladder cancer, prostate cancer, kidney cancer, adrenal gland tumors, etc.), Gynecological tumors (cervical cancer, endometrial cancer, ovarian cancer, etc.), head and neck tumors (nasopharyngeal cancer, laryngeal cancer, thyroid cancer), hematological tumors (lymphoma, bone marrow cancer, leukemia, etc.), other tumors (sarcoma, thyroid cancer, melanoma, brain tumors, etc.)
Shanghai Jiahui International Cancer Center (JICC) CAR-T is led by Dr. Vicky H. Lee (Directorof JICC), an internationally renowned hematologist. JICC provides CAR-T-related diagnosisand treatment services integrating international partner hospitals such as MassachusettsGeneral Hospital in the United States, as well as leveraging local high-quality medicalresources in Shanghai, such as Ruijin Hospital and Tongji Hospital. The services includeoutpatient consultation, screening and evaluation, T-cell collection, CAR-T infusion, sideeffects monitoring and management, etc.Shanghai Jiahui International Hospital has developed a standard service process and qualitycontrol system based on the international CAR-T clinical guidelines, ensuring the customizedtreatment of patients. Additionally, the CAR-T rapid response team has been established, witha multidisciplinary clinical professional team consisting of department heads from the CancerCenter, Neurology, Cardiology, Respiratory Medicine, ICU, Laboratory, Pharmacy, and otherdepartments. Multiple rounds of clinical training and scenario simulations have beenconducted in the early stages to ensure the full process management of CAR-T treatment.Advanced CAR-T extraction equipment and CAR-T special wards have been set up. Bothhardware and software fully guarantee patient monitoring needs and a comfortable experience.Shanghai Jiahui International Cancer Center (JICC) has completed multiple CAR-T trainingcertifications, including FosunKite Bio and IASO Bio, and has been authorized for treatmentcertification, enabling the initiation of clinical applications of CAR-T cell immunotherapy.
- Member of Beijing Medical University (BMU)
- Member of the Washington State Medical Oncology Society (WSMOS)
- Member of the American Society of Clinical Oncology (ASCO)
- Member of the American Society of Hematology (ASH)
- Member of the Oregon Society of Medical Oncology (OSMO)
Dr. [Name] holds an MD from Beijing Medical University (BMU) and has worked at BMU Hospital for three years. She later pursued cancer immunology research at the prestigious Kyoto University School of Medicine in Japan, followed by breast cancer research at New York University School of Medicine in the United States. During her time in the U.S., she achieved board certifications in Internal Medicine, Hematology, and Oncology from the American Board of Internal Medicine (ABIM). In 2018, she received a certificate in Cancer Genetic Risk Assessment from City of Hope. She is licensed to practice medicine in Oregon and Washington State and is internationally renowned in cancer treatment, hematology, and cancer risk assessment.
